BLTE BELITE BIO, INC

Nasdaq belitebio.com


$ 106.39 $ -11.58 (-9.87 %)    

Tuesday, 11-Nov-2025 15:59:54 EST
QQQ $ 624.60 $ 0.00 (0 %)
DIA $ 480.27 $ 0.00 (0 %)
SPY $ 684.80 $ 0.00 (0 %)
TLT $ 89.71 $ 0.00 (0 %)
GLD $ 379.70 $ 0.00 (0 %)
$ 105.76
$ 115.00
$ 106.01 x 2
$ 116.40 x 9
-- - --
$ 49.00 - $ 124.73
75,575
na
3.37B
$ 0.04
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 belite-bio-q3-eps-065-misses-045-estimate

Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.45) ...

 earnings-outlook-for-belite-bio
Earnings Outlook For Belite Bio
11/07/2025 15:02:31

 benchmark-maintains-buy-on-belite-bio-raises-price-target-to-132

Benchmark analyst Bruce D. Jackson maintains Belite Bio (NASDAQ:BLTE) with a Buy and raises the price target from $80 to $132.

 belite-bio-says-center-for-drug-evaluation-of-chinas-nmpa-agrees-to-accept-nda-with-priority-review-for-tinlarebant-for-treatment-of-stargardt-disease-based-on-interim-analysis-results-from-phase-3-dragon-trial

NMPA's response is based on the Phase 3 DRAGON interim analysis resultsTopline final data expected in Q4 2025SAN DIEGO, Oct...

 hc-wainwright--co-maintains-buy-on-belite-bio-lowers-price-target-to-98

HC Wainwright & Co. analyst Yi Chen maintains Belite Bio (NASDAQ:BLTE) with a Buy and lowers the price target from $100 ...

 belite-bio-completes-last-subject-visit-in-phase-3-dragon-clinical-trial-evaluating-tinlarebant-for-treatment-of-stargardt-disease-type-1

Tinlarebant has been granted Breakthrough Therapy, Fast Track, and Rare Pediatric Disease Designations in the U.S.; Orphan Drug...

 belite-bio-announces-125m-pipe-financing-at-64share-with-195m-shares-and-warrants-potential-additional-150m-at-7680share

Transaction led by RA Capital Management with participation from Eventide Asset Management, Marshall Wace, RTW Investments, Sol...

 belite-bio-q2-eps-050-misses-040-estimate

Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.40) ...

 belite-bios-earnings-outlook
Belite Bio's Earnings Outlook
08/08/2025 14:07:37

 hc-wainwright--co-reiterates-buy-on-belite-bio-maintains-100-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Belite Bio (NASDAQ:BLTE) with a Buy and maintains $100 price target.

 belite-bio-enrolls-500-subjects-globally-in-phoenix-trial-advancing-oral-tinlarebant-for-geographic-atrophy-in-dry-age-related-macular-degeneration

500 subjects enrolled across the United States, the United Kingdom, France, Czech Republic, Switzerland, China, Taiwan, and Aus...

 cantor-fitzgerald-reiterates-overweight-on-belite-bioto-overweight

Cantor Fitzgerald analyst Jennifer Kim reiterates Belite Bio (NASDAQ:BLTE) from Overweight to Overweight.

 hc-wainwright--co-reiterates-buy-on-belite-bio-maintains-100-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Belite Bio (NASDAQ:BLTE) with a Buy and maintains $100 price target.

 belite-bio-q1-eps-045-misses-035-estimate

Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.35) ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION